Bms-214662
| Title | Journal |
|---|---|
| Synthesis and biological evaluation of new phenothiazine derivatives bearing a pyrazole unit as protein farnesyltransferase inhibitors. | Bioorganic & medicinal chemistry letters 20121115 |
| Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells. | Journal of molecular medicine (Berlin, Germany) 20120201 |
| The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells. | Leukemia 20110701 |
| Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives. | Journal of medicinal chemistry 20101014 |
| Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. | Anti-cancer agents in medicinal chemistry 20100201 |
| Design, Synthesis and Evaluation of Novel 1-(Substituted Acetyl)-4-(10-Bromo-8-Chloro-5,6-Dihydro-11H-Benzo[5,6]Cyclohepta[1,2-B]Pyridine-11-Ylidene)piperidines as Antitumor Agents and Farnesyl Protein Transferase Inhibitors. | Indian journal of pharmaceutical sciences 20100101 |
| BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta. | Blood 20091105 |
| Analysis of the eukaryotic prenylome by isoprenoid affinity tagging. | Nature chemical biology 20090401 |
| Chronic myelogenous leukemia stem cells: What's new? | Current hematologic malignancy reports 20090401 |
| Ethyl methanesulphonate in a parenteral formulation of BMS-214662 mesylate, a selective farnesyltransferase inhibitor: formation and rate of hydrolysis. | Pharmaceutical development and technology 20090101 |
| BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. | Blood 20080301 |
| Characterization of cancer stem cells in chronic myeloid leukaemia. | Biochemical Society transactions 20071101 |
| Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070615 |
| Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors. | Cancer chemotherapy and pharmacology 20060701 |
| Group IVC cytosolic phospholipase A2gamma is farnesylated and palmitoylated in mammalian cells. | Journal of lipid research 20051001 |
| Development of farnesyl transferase inhibitors: a review. | The oncologist 20050901 |
| Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination. | Molecular pharmacology 20050601 |
| Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050601 |
| Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. | Current drug targets 20050501 |
| Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050420 |
| Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050410 |
| A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050301 |
| [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia]. | Bulletin du cancer 20050301 |
| Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. | Leukemia & lymphoma 20041101 |
| Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells. | Leukemia 20041001 |
| Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. | Biochemistry 20040608 |
| Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models. | Cancer research 20040601 |
| A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040415 |
| Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040401 |
| Synthesis of N,N'-disubstituted 3-aminobenzo[c] and [d]azepin-2-ones as potent and specific farnesyl transferase inhibitors. | Bioorganic & medicinal chemistry letters 20040209 |
| Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors. | Journal of medicinal chemistry 20040129 |
| Farnesyl transferase inhibitors in myeloid malignancies. | Blood reviews 20030901 |
| Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. | Clinical lymphoma 20030801 |
| Preclinical and clinical evaluation of farnesyltransferase inhibitors. | Current oncology reports 20030301 |
| Farnesyl transferase inhibitors in the treatment of breast cancer. | Expert opinion on investigational drugs 20030301 |
| Targeting RAS signalling pathways in cancer therapy. | Nature reviews. Cancer 20030101 |
| BMS-214662 (Bristol-Myers Squibb). | IDrugs : the investigational drugs journal 20030101 |
| Farnesyl transferase inhibitors as anticancer agents. | European journal of cancer (Oxford, England : 1990) 20020901 |
| [New therapeutic targets and strategies in lung cancer]. | Archivos de bronconeumologia 20020801 |
| Agents targeting ras signaling pathway. | Current pharmaceutical design 20020101 |
| Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. | Cancer research 20011015 |
| Farnesyltransferase inhibitors. | Seminars in oncology 20011001 |
| Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. | Journal of medicinal chemistry 20001005 |